Data on withdrawn drugs was faked; says hospital
Data from studies claiming to show drugs such as the withdrawn products Vioxx (rofecoxib) and Bextra (valdecoxib) may been fabricated, reports the Wall Street Journal.
The Massachusetts, USA-based Baystate Medical Center claims its former chief of acute pain Scott Reuben had faked results that were published in anesthesiology journals between 1996 and 2008. The journal Anesthsia & Analgesia has retracted 10 of Dr Reuben's studies and warned about 11 more. Another journal, Anesthesiology, has retracted three of the articles.
The list of drugs involved in the studies under scrutiny includes: Pfizer's Bextra (valdecoxib), Celebrex (celecoxib) and Lyrica (pregabalin); Merck & Co's Vioxx; and Wyeth's Effexor (venlafaxine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze